Spondyloarthropathies — Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis
Citation(s)
Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis